Education
About Us
Working with TipRanks
Follow Us
Biocryst Pharmaceuticals (BCRX)
NASDAQ:BCRX
BCRX Stock Chart & Stats
$7.70
-$0.02(-0.25%)
At close: 4:00 PM EST
$7.70
-$0.02(-0.25%)
Day’s Range― - ―
52-Week Range$6.00 - $11.31
Previous CloseN/A
Volume537.69K
Average Volume (3M)3.81M
Market Cap
$1.62B
Enterprise Value$2.14B
Total Cash (Recent Filing)$212.87M
Total Debt (Recent Filing)$683.11M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Feb 25, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding210,739,060
10 Day Avg. Volume3,918,860
30 Day Avg. Volume3,810,858
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)-3.27
Price to Sales (P/S)3.45
P/FCF Ratio-29.25
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue3.57
Enterprise Value/Gross Profit3.66
Enterprise Value/Ebitda25.50
Forecast
1Y Price Target
$19.45Price Target Upside152.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.13
Revenue Forecast (FY)$618.51M
Bulls Say, Bears Say
Bulls Say
Growth OpportunitiesThe pediatric segment offers an important growth opportunity for Orladeyo, with the current treatment options being less than ideal for children.
Product DiversificationBCX17725 is seen as a call option for BioCryst Pharmaceuticals that can help diversify the company's focus beyond hereditary angioedema.
Strategic AcquisitionThe acquisition of ATXS and its drug navenibart is expected to strengthen BCRX's position in the HAE market.
Bears Say
Competitive FearsCurrent stock reactions reflect competitive fears and controversy on peak sales for both Orladeyo and navenibart.
Demand ConcernsPrior conversations with key opinion leaders indicated more muted demand for prophylactic therapy for pediatric patients due to low attack rates.
Diagnostic ChallengesDiagnosis of Netherton Syndrome remains challenging, which complicates the management and treatment of the disease.
BioCryst News
BCRX FAQ
What was Biocryst Pharmaceuticals’s price range in the past 12 months?
Biocryst Pharmaceuticals lowest stock price was $6.00 and its highest was $11.31 in the past 12 months.
What is Biocryst Pharmaceuticals’s market cap?
Biocryst Pharmaceuticals’s market cap is $1.62B.
When is Biocryst Pharmaceuticals’s upcoming earnings report date?
Biocryst Pharmaceuticals’s upcoming earnings report date is Feb 25, 2026 which is in 60 days.
How were Biocryst Pharmaceuticals’s earnings last quarter?
Biocryst Pharmaceuticals released its earnings results on Nov 03, 2025. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02.
Is Biocryst Pharmaceuticals overvalued?
According to Wall Street analysts Biocryst Pharmaceuticals’s price is currently Undervalued.
Does Biocryst Pharmaceuticals pay dividends?
Biocryst Pharmaceuticals does not currently pay dividends.
What is Biocryst Pharmaceuticals’s EPS estimate?
Biocryst Pharmaceuticals’s EPS estimate is 0.04.
How many shares outstanding does Biocryst Pharmaceuticals have?
Biocryst Pharmaceuticals has 210,739,060 shares outstanding.
What happened to Biocryst Pharmaceuticals’s price movement after its last earnings report?
Biocryst Pharmaceuticals reported an EPS of $0.06 in its last earnings report, beating expectations of $0.04. Following the earnings report the stock price went down -6.284%.
Which hedge fund is a major shareholder of Biocryst Pharmaceuticals?
Currently, no hedge funds are holding shares in BCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioCryst Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.45 (152.60% Upside)
$19.45 (152.60% Upside)
Blogger Sentiment
Bullish
BCRX Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 7.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $367.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 79.3%
Last 30 Days ▲ 79.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.13%
Trailing 12-Months
Company Description
Biocryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
BCRX Company Deck
BCRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflected a strong performance by BioCryst with significant revenue growth, successful financial maneuvers, and promising pipeline developments. However, there were some challenges, including enrollment delays and increased costs. Overall, the company's positive results and strategic decisions indicate a promising outlook.View all BCRX earnings summariesBCRX Stock 12 Month Forecast
Average Price Target
$19.45
▲(152.60% Upside)
Technical Analysis
Vericel
―
Celldex
―
Sarepta Therapeutics
―
Aurinia Pharmaceuticals
―
Cidara Therapeutics
―
Ownership Overview
1.73% Insiders
17.54% Mutual Funds
28.29% Other Institutional Investors
34.12% Public Companies and Individual Investors